Shavit Capital

MeMed Diagnostics Ltd. is a personalized diagnostics company founded in 2009 and based in Tirat Carmel, Israel. The company develops innovative diagnostic solutions aimed at improving patient care and reducing healthcare costs, particularly through the prevention of antibiotic misuse. MeMed's flagship products include MeMed BV, a test that differentiates between bacterial and viral infections, and the ImmunoDx platform, which utilizes proprietary biomarkers and algorithms to analyze the immune system's responses to pathogens. This technology addresses significant challenges in infectious disease diagnostics, providing rapid and actionable insights that enable healthcare providers to make informed decisions regarding antibiotic treatments. By accurately identifying infection sources, MeMed aims to combat the inappropriate prescription of antibiotics, which contributes to the emergence of resistant bacterial strains and incurs substantial costs to healthcare systems worldwide.

Lightricks Ltd. is a mobile application developer based in Jerusalem, Israel, specializing in image processing and creativity tools that enhance visual content creation. Founded in 2013 by a team of entrepreneurs with expertise in computer graphics, image processing, machine learning, and artificial intelligence, the company offers a range of popular applications, including Facetune, Enlight, and Beatleap. These applications integrate advanced technologies such as computer vision and augmented reality, allowing users to easily edit and customize their photos and videos. Lightricks' portfolio includes tools for both personal and professional use, catering to individual users and small businesses alike, facilitating engagement and creativity through user-friendly mobile solutions.

KAHR Medical Ltd. is an immuno-oncology drug development company based in Jerusalem, Israel, founded in 2005. The company focuses on creating fusion protein pharmaceuticals aimed at treating cancer and autoimmune diseases. KAHR develops innovative drugs such as DSP105 and DSP106, which facilitate T-cell mediated tumor destruction, and DSP107, which targets CD47 tumors to activate phagocytes while delivering an immune costimulatory signal. Utilizing a unique platform of multifunctional immuno-recruitment proteins, KAHR's technology aims to enhance immune system recognition of cancer cells, thereby addressing the challenge of cancer evasion. This approach represents a significant advancement in protein-based pharmaceuticals, expanding treatment options for patients facing these serious health conditions.

Veev Inc., established in 2017 and located in Minneapolis, Minnesota, is a building technology company focused on transforming the construction and experience of homes. It offers a comprehensive home operating system that integrates room-specific lighting, climate control, and security features, addressing a wide range of smart housing needs. Veev utilizes innovative materials such as light gauge steel for framing and high performance acrylic for surfaces, alongside advanced systems for radiant climate control. The company's offerings include a panelized building system and a digital ecosystem that enhances home management, safety, and maintenance. Currently, Veev is concentrating on high-performance multifamily units and accessory dwelling units (ADUs), with a development pipeline that encompasses over 230 units and 620,000 gross building square feet.

Alpha Tau Medical is an Israeli medical device company established in 2016 and headquartered in Tel Aviv. The company specializes in researching, developing, and commercializing a novel treatment known as Alpha DaRT, or Diffusing Alpha-emitters Radiation Therapy, aimed at addressing solid tumors. This innovative technology utilizes interstitial radioactive seeds to deliver targeted radiation therapy, capitalizing on the unique properties of alpha particles, which have a short range but high biological effectiveness. Since its inception, Alpha Tau Medical has conducted numerous preclinical studies demonstrating the safety and efficacy of its approach, with findings published in various peer-reviewed journals. The company is currently advancing its clinical trials, which have shown promising preliminary results, and it primarily generates revenue from its operations in Israel.

Syqe Medical Ltd., established in 2011 and headquartered in Tel Aviv, Israel, focuses on transforming cannabis and other psychoactive botanicals into mainstream medical treatments. The company has developed the Syqe Inhaler Exo, a metered-dose inhaler designed for professional healthcare use in settings such as pain clinics, cancer centers, and intensive care units. This innovative inhaler allows for precise delivery of therapeutic molecules, enabling patients to achieve effective symptom relief while minimizing psychoactive side effects. By employing advanced technology and automation, Syqe Medical ensures consistent and predictable treatment outcomes at pharmaceutical standards, contributing to the decentralization of drug development in the medical cannabis industry.

Alpha Tau Medical is an Israeli medical device company established in 2016 and headquartered in Tel Aviv. The company specializes in researching, developing, and commercializing a novel treatment known as Alpha DaRT, or Diffusing Alpha-emitters Radiation Therapy, aimed at addressing solid tumors. This innovative technology utilizes interstitial radioactive seeds to deliver targeted radiation therapy, capitalizing on the unique properties of alpha particles, which have a short range but high biological effectiveness. Since its inception, Alpha Tau Medical has conducted numerous preclinical studies demonstrating the safety and efficacy of its approach, with findings published in various peer-reviewed journals. The company is currently advancing its clinical trials, which have shown promising preliminary results, and it primarily generates revenue from its operations in Israel.

Anchiano Therapeutics Ltd. is a preclinical biotechnology company based in Cambridge, Massachusetts, that focuses on discovering, developing, and commercializing small molecule anti-cancer therapies. The company primarily works on the Pan-RAS Program, which aims to develop novel indene-based small molecules that inhibit activated RAS signaling across various isoforms and mutations. Additionally, Anchiano is advancing a PDE10/ß-catenin program targeting small molecules that selectively inhibit PDE10 and suppress Wnt/APC/ß-catenin signaling. The company has established a collaboration and license agreement with ADT Pharmaceuticals to further research these programs. Founded in 2004 and originally known as BioCancell Ltd., Anchiano Therapeutics aims to provide targeted cancer therapies that selectively destroy cancer cells while sparing healthy cells, utilizing specific gene expressions found predominantly in tumors. Its lead drug candidate, BC-819, has completed a Phase IIb clinical trial for bladder cancer, with ongoing investigations into other cancer types.

Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.

PolyPid Ltd. is a clinical-stage biopharmaceutical company based in Petach Tikva, Israel, specializing in the development of innovative drug delivery systems using its proprietary Polymer-Lipid Encapsulation Matrix (PLEX) technology. Founded in 2008, PolyPid focuses on creating products that enable controlled and prolonged release of active pharmaceutical ingredients (APIs) for various healthcare applications. The company's flagship products include D-PLEX, designed to prevent and treat surgical site infections, and BONYPID, which addresses bone-related infections through antibiotic-eluting granules and substitutes. PolyPid's technology allows for localized administration of drugs with pre-determined release rates, optimizing treatment regimens across different therapeutic areas. Additionally, the company is exploring other product candidates, including OncoPLEX for potential intra-tumoral therapy.

Mapi Pharma is a development-stage pharmaceutical company focused on creating high-barrier, high-value generic drugs that encompass complex active pharmaceutical ingredients (APIs), formulations, and life cycle management products. The company leverages its strong research and development capabilities, along with a comprehensive understanding of global market dynamics and regulatory requirements, to establish lasting partnerships in multiple countries. Mapi's offerings include both generic and innovative intermediates and APIs, as well as finished dosage forms developed for its internal API program or as generics of established brands. Headquartered in Israel, Mapi operates R&D facilities in Israel, China, and Germany, and is currently developing an API manufacturing site in Neot Hovav, Israel. The company maintains a robust intellectual property portfolio, with numerous patent applications filed for its APIs and formulations, aimed at enhancing patient compliance and minimizing side effects through advanced sterile production processes.